CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
实体瘤的 CAR 免疫治疗——新兴靶点综述
英文原题：CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets.
查看英文原题
CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞免疫疗法已彻底改变B细胞和浆细胞来源癌症的治疗。然而，实体瘤给CAR工程化免疫细胞治疗带来了更大的挑战。在一篇配套综述中，我们调查了针对表达30种不同靶点的实体瘤患者开展CAR免疫疗法临床试验所产生的数据。该分析证实，这种方法的疗效远低于其在血液系统恶性肿瘤中取得的疗效，同时也报告了显著毒性事件。本文考察约60种其他候选靶点，目前尚无此类靶点的临床数据，但临床前数据已支持将其作为CAR靶抗原推进临床评估。
展开英文摘要原文
Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers.
However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported.
Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.
论文信息
- 作者
- Maher J、Davies DM
- 第一作者单位
- CAR Mechanics Group, Guy's Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, Great Maze Pond, London SE1 9RT, UK.United Kingdom
- 通讯作者单位
- Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.United Kingdom
- 文献类型
- 综述
- 期刊
- Cancers2023 Feb 11
- 原文标识
- PubMed 36831514 · DOI 10.3390/cancers15041171
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →